Halozyme's 48% Q2 Jump Looks Real-But the Next Move Hinges on One Simple Question

The quarter cleared the bar on revenue and earnings

Halozyme posted Q2 revenue of $481.0 million, up 48% year over year, versus a Wall Street estimate near $409.6 million. Adjusted EPS was $2.28, ahead of the $1.80 estimate. This was not a narrow beat.

The bigger point is that management also raised all four full-year guidance ranges, including non-GAAP diluted EPS guidance of $8.65 to $9.00 and revenue guidance of $1.835 billion to $1.910 billion. Bulls can read that as evidence of real demand rather than a one-off quarter. Bears are still right to note that one strong report does not settle the case, but a raise makes the next few quarters more important.

With the Nov. 2, 2026 earnings call still ahead, the key question is straightforward: can Halozyme back up this quarter with another period of strong execution?

Royalty growth and new deals show the platform is still gaining traction

Royalty revenue is the clearest read-through

For Halozyme, the best signal is not just headline revenue. It is the sales from partner products that turn into royalties. By that measure, the quarter was strong. Royalty revenue increased 50% to $307.7 million, while adjusted EBITDA rose 46% to $328.8 million. That matters because royalty growth depends on partners launching products, expanding use, or selling more volume.

It also helps to note that royalties were the larger part of the mix. Royalty revenue represented about 64% of quarterly revenue, and the increase was tied to continued adoption of ENHANZE partner products launched since 2020, particularly argenx's VYVGART Hytrulo and Janssen's DARZALEX SC. That gives the quarter more substance than a single product or accounting effect could.

New sign-ups are still adding to the pipeline

Halozyme also said it had signed five new ENHANZE and Hypercon collaboration agreements through July, ahead of its goal of three for full-year 2026. The named partners were Vertex, Oruka, GSK, Incyte and an undisclosed partner.

A signed agreement is not the same as revenue, but five new deals before the year is halfway gone is still a strong operating signal. It suggests demand for Halozyme's delivery platform remains broad, even as investors look for proof points that are easier to underwrite.

The main risk is margin pressure, not top-line momentum

The most credible bear case is not weak revenue. It is whether growth remains efficient.

Operating margin fell to about 59.8% from about 62.2% a year earlier, even though operating income still increased. That kind of spread change matters. If expenses start rising faster than revenue, the market may stop paying up for growth alone and start focusing more on efficiency.

Some cost pressure looks temporary

Product costs, acquisition-related expenses and litigation-related professional fees rose. That makes the quarter look messier than the headline revenue and EPS figures suggest.

The important distinction is whether these costs are temporary noise or a new baseline. If revenue keeps climbing, a few one-off expense items matter less over time. If they persist, investors will need clearer proof that Halozyme can grow without a steady drop in profitability.

What to watch next

At the Nov. 2, 2026 earnings call, the key checkpoints are simple:

• Does operating margin stabilize instead of sliding again?
• Are acquisition and litigation costs staying contained?
• Is cost of sales moving in line with the business mix, or pulling ahead?

If those items hold, this quarter looks like the start of a stronger streak rather than a one-quarter outlier. If not, the story shifts from platform momentum to execution management.